Wound Management Technologies, Inc. Announces Agreement with Dr. Leland Shapiro, MD

FORT WORTH, Texas, Sept. 3 Wound CareInnovations, LLC, a subsidiary of Wound Management Technologies, Inc.,(OTC Bulletin Board: WNDM), announced today that it has signed an agreementwith Dr. Leland Shapiro, MD to conduct studies on their advanced wound carecollagen product, CellerateRx(R). Dr. Shapiro, Associate Professor ofMedicine at the University of Colorado Denver School of Medicine and theDenver Veteran's Affairs Medical Center, has published extensively on factorsaffecting cell cytokine induction and suppression. He has over 35 originalpublications in peer reviewed journals as well as reviews and book chapters inleading authoritative texts. "Dr. Shapiro is a leading authority andrecognized in his field worldwide," stated Cathy Bradshaw, President of WoundCare Innovations. "We are very excited about this agreement and theopportunity to work with Dr. Shapiro and his team in these evaluations ofCellerateRx(R)."

About Wound Management Technologies, Inc.:

Wound Management Technologies, Inc. (WNDM), with its corporateheadquarters in Fort Worth, Texas, markets and distributes wound care productsto the healthcare market under patented technology licensed to the Company.The Company is positioned and seeks to be a leading provider of wound careproducts. For more information on the Company please visit the Company'sWebsite at www.Celleraterx.com .

"Safe Harbor" Statement: Under The Private Securities Litigation ReformAct of 1995: The statements in the press release that relate to the company'sexpectations with regard to the future impact on the company's results fromnew products in development are "forward-looking statements," within themeaning of the Private Securities Litigation Reform Act of 1995. Since thisinformation may contain statements that involve risk and uncertainties and aresubject to change at any time, the company's actual results may differmaterially from expected results. This document may contain forward-lookingstatements concerning the Company's operations, current and future performanceand financial condition. These items involve risks and uncertainties such asproduct demand, market and customer acceptance, the effect of economicconditions, competition, pricing, the ability to consummate and integrateacquisitions, and other risks and uncertainties detailed in the Company's SECfilings. The Company undertakes no obligation to revise any of thesestatements to reflect the future circumstances or the occurrence ofunanticipated events.Product Information Shareholder Relations Cathy Bradshaw Lucy Singleton President Secretary 954-315-9242 817-820-7080

SOURCE Wound Management Technologies, Inc.

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...